KR102861339B1 - 삼치환 벤조트리아졸 유도체의 사용 방법 - Google Patents

삼치환 벤조트리아졸 유도체의 사용 방법

Info

Publication number
KR102861339B1
KR102861339B1 KR1020207024137A KR20207024137A KR102861339B1 KR 102861339 B1 KR102861339 B1 KR 102861339B1 KR 1020207024137 A KR1020207024137 A KR 1020207024137A KR 20207024137 A KR20207024137 A KR 20207024137A KR 102861339 B1 KR102861339 B1 KR 102861339B1
Authority
KR
South Korea
Prior art keywords
cancer
pharmaceutical composition
composition according
cell lymphoma
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207024137A
Other languages
English (en)
Korean (ko)
Other versions
KR20200123137A (ko
Inventor
다니엘 울라넷
성 은 최
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20200123137A publication Critical patent/KR20200123137A/ko
Application granted granted Critical
Publication of KR102861339B1 publication Critical patent/KR102861339B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207024137A 2018-02-20 2019-02-19 삼치환 벤조트리아졸 유도체의 사용 방법 Active KR102861339B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2018018679 2018-02-20
USPCT/US2018/018679 2018-02-20
PCT/US2019/018472 WO2019164794A1 (en) 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives

Publications (2)

Publication Number Publication Date
KR20200123137A KR20200123137A (ko) 2020-10-28
KR102861339B1 true KR102861339B1 (ko) 2025-09-19

Family

ID=61692059

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024137A Active KR102861339B1 (ko) 2018-02-20 2019-02-19 삼치환 벤조트리아졸 유도체의 사용 방법

Country Status (13)

Country Link
US (2) US11717512B2 (https=)
EP (1) EP3755324B1 (https=)
JP (2) JP7434185B2 (https=)
KR (1) KR102861339B1 (https=)
CN (1) CN111757731B (https=)
AU (1) AU2019223906B2 (https=)
BR (1) BR112020016929A8 (https=)
CA (1) CA3091792A1 (https=)
ES (1) ES3038736T3 (https=)
MA (1) MA51897A (https=)
MX (1) MX2020008678A (https=)
TW (1) TWI818954B (https=)
WO (1) WO2019164794A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA48459B1 (fr) * 2017-04-24 2021-09-30 Aurigene Discovery Tech Ltd Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
KR102861339B1 (ko) 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
PE20212197A1 (es) * 2018-12-21 2021-11-16 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo
CN111662872A (zh) * 2020-05-06 2020-09-15 西南医科大学附属医院 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法
CA3184024A1 (en) * 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) * 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224663A1 (en) * 2013-02-25 2017-08-10 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035419A1 (en) 1995-05-10 1996-11-14 Pfizer Inc. Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
JP2003510352A (ja) 1999-10-01 2003-03-18 インスティチュート オブ モレキュラー アンド セル バイオロジー ウイルス媒介性疾病の治療用化合物
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
PL382308A1 (pl) * 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
ATE474833T1 (de) 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
EP2066319B1 (en) 2006-09-08 2012-02-01 F. Hoffmann-La Roche AG Benzotriazole kinase modulators
EP2387568A1 (en) 2009-01-19 2011-11-23 NeuroSearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
WO2010115736A2 (en) 2009-04-02 2010-10-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
JP5967827B2 (ja) 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
CN103476770B (zh) 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
WO2013049112A1 (en) 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PL3139914T3 (pl) 2014-05-08 2023-11-27 Kiora Pharmaceuticals Gmbh Związki stosowane w leczeniu chorób i schorzeń okulistycznych
WO2017037022A1 (en) * 2015-09-01 2017-03-09 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers
EP3397625A4 (en) 2015-12-30 2019-12-25 Agios Pharmaceuticals, Inc. TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
MA48459B1 (fr) 2017-04-24 2021-09-30 Aurigene Discovery Tech Ltd Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
KR102861339B1 (ko) * 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
JP7608336B2 (ja) 2018-11-30 2025-01-06 フォンダッツィオーネ・セントロ・サン・ラッファエーレ 中枢神経系原発リンパ腫の併用治療
PE20212197A1 (es) 2018-12-21 2021-11-16 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo
WO2021062157A1 (en) 2019-09-27 2021-04-01 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
CA3184024A1 (en) 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224663A1 (en) * 2013-02-25 2017-08-10 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors

Also Published As

Publication number Publication date
BR112020016929A8 (pt) 2022-06-28
TWI818954B (zh) 2023-10-21
CN111757731B (zh) 2024-06-25
KR20200123137A (ko) 2020-10-28
MA51897A (fr) 2020-12-30
AU2019223906A1 (en) 2020-09-10
JP2023109974A (ja) 2023-08-08
US20240148697A1 (en) 2024-05-09
US11717512B2 (en) 2023-08-08
US20210113531A1 (en) 2021-04-22
AU2019223906B2 (en) 2024-11-21
JP2021514395A (ja) 2021-06-10
US12290508B2 (en) 2025-05-06
CN111757731A (zh) 2020-10-09
ES3038736T3 (en) 2025-10-14
EP3755324B1 (en) 2025-07-30
BR112020016929A2 (pt) 2020-12-15
CA3091792A1 (en) 2019-08-29
WO2019164794A1 (en) 2019-08-29
EP3755324A1 (en) 2020-12-30
MX2020008678A (es) 2020-09-25
TW201938543A (zh) 2019-10-01
EP3755324C0 (en) 2025-07-30
JP7434185B2 (ja) 2024-02-20

Similar Documents

Publication Publication Date Title
KR102861339B1 (ko) 삼치환 벤조트리아졸 유도체의 사용 방법
US20180303840A1 (en) Combination therapy for treating malignancies
JP2020517652A (ja) 併用療法
CN106660991A (zh) 抗增殖化合物及其使用方法
JP2023504046A (ja) ジアリール大環状化合物を含む併用療法
WO2025157289A1 (zh) 包含prmt5抑制剂和krasg12c抑制剂的药物组合物
TW202329969A (zh) 用於治療急性髓系白血病的ＦＬＴ３抑制劑和Ｂｃｌ－３抑制劑的治療有效組合
US20130101680A1 (en) Radiotherapy enhancer
JP2018511642A (ja) 癌を治療するための方法
CN112121052B (zh) 丙烯酰基苯并氮杂䓬类化合物在制备防治血液肿瘤药物中的用途
HK40043674A (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
HK40043674B (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
WO2024028846A1 (en) Combination therapy for treating cancers
AU2006231809B2 (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient
KR102687556B1 (ko) 종양 전이를 억제하는 방법
TWI401085B (zh) Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents
KR102960038B1 (ko) 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안
EP3777852A1 (en) Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers
WO2025070603A1 (ja) 血液がんの新規併用療法
HK1118807B (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

G15 Pta requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G15-TAD-PA0102 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0102 Application to register extension of term of patent right following delayed registration

St.27 status event code: A-4-4-G10-G15-tad-PA0102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 96

G17 Pta granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G17-TAD-PR1102 (AS PROVIDED BY THE NATIONAL OFFICE)

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 96